ArticleFrontiers in immunology2020

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.

Katja Akgün et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.